Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ferroquine (SSR97193)
ferroquine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ferroquine (SSR97193) | DRUG | associated with artesunate |
| amodiaquine | DRUG | associated with artesunate |
Inclusion Criteria: * Body weight between 50 kg and 90 kg with Body Mass Index \>18 kg/m² * Presence of body temperature ≥ 37.5°C or history of fever within the last 24 hours * Monoinfection with Plasmodium falciparum and parasitemia within the 100 to 200,000/microL Exclusion Criteria: * Hypersen...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 4 | PHASE3 | Tafenoquine, GSK3772701, Mosquirix, GSK4425689A |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
Ferroquine is an investigational small molecule being developed for the treatment of malaria. It has been studied in adult patients with uncomplicated malaria, where it was given in combination with artesunate. Ferroquine is not yet an approved medicine and remains in clinical development.
Ferroquine is being developed by Sanofi, the French pharmaceutical company whose shares trade under the ticker SNY. Sanofi holds the compound, which is also referenced in the literature by its internal code SSR97193. Development has focused on malaria as the target indication within the infectious disease therapeutic area.
Ferroquine is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. Because the program has not advanced beyond Phase 1, ferroquine is investigational and is not an approved treatment for malaria or any other indication.
Ferroquine has been evaluated in one completed clinical trial, NCT00563914. That Phase 1 study compared ferroquine combined with artesunate against amodiaquine combined with artesunate in African adult male patients with uncomplicated malaria. It was randomized, actively controlled, and enrolled 72 participants across Gabon and Kenya.
Yes. Ferroquine is also known by the code SSR97193, and the two names refer to the same investigational antimalarial compound. Searches for either name, including the combined form ferroquine (SSR97193), point to the same Sanofi development program for malaria.
Ferroquine was tested in NCT00563914, a completed Phase 1 study in African adults with uncomplicated malaria. Participants were randomized to ferroquine plus artesunate or amodiaquine plus artesunate, an active control. The trial enrolled 72 patients, was not double blinded, and was conducted in Gabon and Kenya.